Form 4: Hepion Pharmaceuticals Director Michael Purcell Acquires 50,000 Restricted Stock Units
SEC Form 4 Filing
Director Michael J. Purcell of Hepion Pharmaceuticals acquired 50,000 restricted stock units (RSUs) on March 6, 2024, which convert to common stock upon vesting.
Summary
- On March 6, 2024, Michael J. Purcell, a director of Hepion Pharmaceuticals, Inc., was granted 50,000 restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of Hepion Pharmaceuticals common stock.
- The RSUs will vest upon the earlier of (i) one year from the date of grant or (ii) a change of control of the Issuer.
- Following the transaction, Purcell directly owns 50,000 derivative securities.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock options granted to a director. It's neutral in tone and doesn't indicate any significant positive or negative developments.
Positives
- The grant of RSUs to a director aligns their interests with those of the shareholders.
- The vesting conditions (time-based or change of control) are standard and reasonable.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Restricted stock units are a standard form of equity compensation, similar to grants made by companies like Amgen, Gilead Sciences, and Biogen to their directors and executives.
- Vesting schedules tied to time or change of control are also typical in the industry.
Stakeholder Impact
- The grant of RSUs could have a slightly dilutive effect on existing shareholders, but it also incentivizes the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction: Michael J. Purcell was granted 50,000 restricted stock units. |
| 03/07/2024 | Date of signature: The Form 4 was signed on March 7, 2024. |
Keywords
Hepion Pharmaceuticals, Michael J. Purcell, restricted stock units, RSUs, director, beneficial ownership, Form 4, HEPA, stock options, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.